Bollé Safety, the PPE Eyewear Specialists Introduce Go Green: Concrete Actions to Protect the Environment
25.5.2021 11:45:00 EEST | Business Wire | Press release
Bollé Safety wants to do its part to protect the planet. In 2021, the global brand for eye protection is kicking into high gear with their Go Green plan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005026/en/
Sustainability: a long-term process
Bollé Safety’s products have been packaged in recyclable BPA-free plastic bags since 2005. But as a company selling millions of units annually, they wish to do more on every aspect of their production and distribution processes.
With the Go Green program, all of their eco-friendly improvements add up to reach one goal: become a certified B Corporation by 2023, and meet the most rigorous standards of environmental performance, for their stakeholders benefits.
Focusing on green research and development
Their R&D and production departments are committed to developing more environmentally-friendly materials, products and processes, while always preserving the quality and protection they offer.
Introducing the Ecopack: 100% recyclable packaging made from recycled cardboard and tissue paper. The user-instruction is printed directly on the overwrap with vegetal-based ink to avoid all plastic. By optimizing their product design, they also reduce the amount of raw material required during production, as well as the packaging weight. It produces 30% less waste than before, improving their carbon footprint during transportation.
More sustainable technologies and raw materials
Focus on eco-friendly products: SOLIS and KLASSEE. With its nylon frame made from 100% recycled fishing nets, SOLIS is EN166-compliant and embodies the company’s R&D effort towards sustainability. KLASSEE’s (prescription) bio-based frame is made from castor oil.
Extra efforts: By using the latest technologies, they also reduce energy consumption and waste production during manufacturing (injection, molding). Some of the coatings are water-based to reduce the use of chemicals when possible.
Sustainability has never been more necessary than today. It is time for action. This is the reason why Bollé Safety decided, as a company, to become more conscious.
To find out more about our actions, visit https://bit.ly/3vuHanQ
About Bollé Safety
Bollé Safety, the global brand for eye protection since 1888.
With a wide range of innovative, comfortable and protective safety and prescription eyewear, we are trusted with the protection of over 20 million workers’ vision in 100 countries. It is our duty to make a difference, for you and for the future of our Planet.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005026/en/
Contact information
Press
Aline CAMPO/Robin SAUNIER-PLUMAZ
+33-(0)7-64-55-36-09/+33-(0)7-64-55-36-09
E-mail: press@bolle-safety.com
bolle-safety.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom